Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025DrugsOpen Access

Pharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis

View Full Paper
Ask AI
Bookmark
Share

Authors

SJS. JouneauPCPierre ChauvinMLMathieu Léderlin

Discussion

Loading...

Member takes

Overview

Assessment of pharmacotherapy strategies for autoimmune pulmonary alveolar proteinosis, highlighting new therapies.

Key Points

  • Inhaled granulocyte-macrophage colony-stimulating factor has emerged as a first-line treatment for pulmonary alveolar proteinosis.
  • Whole lung lavage remains essential for respiratory failure cases, especially at diagnosis; about 66% improve post-procedure.
  • Autoimmune pulmonary alveolar proteinosis can be effectively diagnosed through bronchoalveolar lavage analysis.
  • Emerging therapies like PPARγ agonists may expand treatment options significantly for pulmonary alveolar proteinosis.

Cite This Study

Jouneau et al. (2025) studied this question.

synapsesocial.com/papers/68c2384fb210217d64776d5bhttps://doi.org/10.1007/s40265-025-02228-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recent advances in the diagnosis and management of pulmonary alveolar proteinosis2025
  2. 2Targeting autoimmune pulmonary alveolar proteinosis with GM-CSF: insights from clinical trials and emerging therapies2026
  3. 3Pulmonary alveolar proteinosis with atypical clinical and bronchoscopic features2025 · 1 citations
  4. 4GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis2025
  5. 5Autoimmune Pulmonary Alveolar Proteinosis (PAP)2025